Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC25A28 divergent transcript (SLC25A28-DT)
- Target
- SLC25A28-DT
- Molecular classification
- Long non-coding RNA (lncRNA), divergent transcript
01
Overview
SLC25A28 divergent transcript (SLC25A28-DT) is a long non-coding RNA gene classified as a divergent transcript, meaning it is transcribed antisense and in close proximity to the SLC25A28 protein-coding gene on human chromosome 10. Divergent transcripts are a subclass of lncRNAs that arise from bidirectional transcription at promoters, often within 300–500 nucleotides of the partner coding gene, and may play regulatory roles, but specific functions for SLC25A28-DT have not been elucidated. As a non-coding RNA, it does not encode a protein and is not currently a recognized therapeutic target[1][2][5].
- Other names
- SLC25A28-DTSLC25A28 divergent transcript
02
Mechanism of action
not applicable
03
Biological functions
Not well-characterized; in general, divergent lncRNAs may have roles in gene regulation, chromatin structure, or the expression modulation of adjacent protein-coding genes
04
Disease associations
Unknown; no prominent associations with cancer, inflammation, neurodegeneration, or other diseases are described in the available literature
Beyond the preview
Go deeper on SLC25A28 divergent transcript (SLC25A28-DT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLC25A28 divergent transcript (SLC25A28-DT).